LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP

被引：0

作者：

Fleischmann, Roy ^{[1
]}

Lin, Yong ^{[2
]}

St John, Gregory ^{[3
]}

van der Heijde, Desiree ^{[4
]}

Qiu, Chunfu ^{[5
]}

Carlos Gomez-Reino, Juan ^{[6
]}

Antonio Maldonado-Cocco, Jose ^{[7
]}

Stanislav, Marina ^{[8
]}

Seriolo, Bruno ^{[9
]}

Tranter, Lesley ^{[10
]}

Burmester, Gerd R. ^{[11
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA

[2] Sanofi Genzyme, Clin, Bridgewater, NJ USA

[3] Regeneron Pharmaceut Inc, Med Affairs, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[4] Leiden Univ, Med Ctr, Rheumatol, Leiden, Netherlands

[5] Sanofi Genzyme, Biostat, Bridgewater, NJ USA

[6] Complejo Hosp Univ Santiago Compostela, IDIS, Santiago, Spain

[7] Buenos Aires Univ, Sch Med, Buenos Aires, DF, Argentina

[8] Res Rheumatol Inst Na VA Nassonova, Rheumatol, Moscow, Russia

[9] Univ Genoa, Internal Med, Genoa, Italy

[10] Sanofi Genzyme, Rheumatol, Oxford, England

[11] Charite Univ Med Berlin, Rheumatol & Clin Immunol, Berlin, Germany

来源：

RHEUMATOLOGY | 2019年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

081

引用

页数：2

共 29 条

[1] LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
Fleischmann, Roy
Lin, Yong
St John, Gregory
van der Heijde, Desiree
Qiu, Chunfu
Jose Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Stanislav, Marina
Seriolo, Bruno
Burmester, Gerd Ruediger
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1130 - 1131
[2] Long-Term Safety with Sarilumab Plus Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) and Sarilumab Monotherapy in Rheumatoid Arthritis (RA): An Integrated Analysis with 9,000 Patient-Years (Pt-Yrs) of Follow-up
Fleischmann, Roy
Lin, Yong
St John, Gregory
van der Heijcle, Desiree
Qiu, Chunfu
Jose Gomez-Reino, Juan
Maldonado-Cocco, Jose A.
Stanislav, Marina
Seriolo, Bruno
Burmester, Gerd R.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[3] Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-up
Fleischmann, Roy
Genovese, Mark C.
Lin, Yong
St John, Gregory
van der Heijde, Desiree
Wang, Sheldon
Jose Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Stanislav, Marina
Kivitz, Alan J.
Burmester, Gerd R.
[J]. RHEUMATOLOGY, 2020, 59 (02) : 292 - 302
[4] LONG-TERM TREATMENT WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS): POOLED SAFETY AND EFFICACY WITH OVER 4 YEARS' TREATMENT
van Hoogstraten, Hubert
St John, Gregory
Thangavelu, Karthinathan
Jose Gomez-Reino, Juan
Antonio Maldonado-Cocco, Jose
Carlos Salazar, Juan
Huizinga, Thomas
Wilson, Elaine
Burmester, Gerd R.
[J]. RHEUMATOLOGY, 2019, 58 : 74 - 75
[5] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
Ernest Choy
Nick Freemantle
Clare Proudfoot
Chieh-I Chen
Laurence Pollissard
Andreas Kuznik
Hubert van Hoogstraten
Erin Mangan
Paulo Carita
Thi-Minh-Thao Huynh
[J]. Advances in Therapy, 2019, 36 : 817 - 827
[6] Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
Choy, Ernest
Freemantle, Nick
Proudfoot, Clare
Chen, Chieh-I
Pollissard, Laurence
Kuznik, Andreas
van Hoogstraten, Hubert
Mangan, Erin
Carita, Paulo
Thi-Minh-Thao Huynh
[J]. ADVANCES IN THERAPY, 2019, 36 (04) : 817 - 827
[7] Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis
Curtis, Jeffrey
Lin, Yong
Thangavelu, Karthinathan
Stanislav, Marina
St John, Gregory
Gomez-Centeno, Antonio
Selmi, Carlo
Huizinga, Thomas
Antonio Maldonado-Cocco, Jose
Bukhari, Marwan
Buttgereit, Frank
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
[8] WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS
Curtis, Jeffrey R.
Lin, Yong
Thangavelu, Karthinathan
Stanislav, Marina
St John, Gregory
Gomez-Centeno, Antonio
Selmi, Carlo
Huizinga, Thomas
Antonio Maldonado-Cocco, Jose
Bukhari, Marwan
Buttgereit, Frank
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 702 - 703
[9] Long-Term Treatment with Sarilumab Plus Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs): Pooled Safety and Efficacy with over 4 Years' Treatment
Genovese, Mark C.
van Hoogstraten, Hubert
St John, Gregory
Dong, Qunming
Jose Gomez-Reino, Juan
Maldonado-Cocco, Jose A.
Carlos Salazar, Juan
Huizinga, Tom W. J.
Burmester, Gerd R.
[J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
[10] A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population
Kivitz, Alan J.
Cohen, Stanley
Keystone, Edward
van Vollenhoven, Ronald F.
Haraoui, Boulos
Kaine, Jeffrey
Fan, Haiyun
Connell, Carol A.
Bananis, Eustratios
Takiya, Liza
Fleischmann, Roy
[J]. SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (03) : 406 - 415

← 1 2 3 →